A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19 (COViNOX)
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo in Subjects With Mild or Moderate Coronavirus (COVID-19)
Sponsor: Bellerophon Pulse Technologies
Terminated
Futility
Other terminated trials from Bellerophon Pulse Technologies
- Pulmonary Fibrosis · Phase PHASE3 · Jun 2023
- Pulmonary Arterial Hypertension · Phase PHASE3 · Aug 2018
More terminations from Bellerophon Pulse Technologies
This PHASE3 trial investigates COVID-19 and Coronavirus and is currently terminated or withdrawn. Bellerophon Pulse Technologies leads this study, which shows 10 recorded versions since 2020 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Mar 2023 — Jul 2024 [monthly]
Terminated PHASE3
-
May 2021 — Mar 2023 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Feb 2021 — May 2021 [monthly]
Active Not Recruiting PHASE3
▶ Show 5 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE3
-
Aug 2020 — Sep 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jul 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bellerophon Pulse Technologies
For direct contact, visit the study record on ClinicalTrials.gov .